BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24354682)

  • 21. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
    Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
    Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.
    Grellier JF; Vercellino L; Leblanc T; Merlet P; Thieblemont C; Weinmann P; Toubert ME; Berenger N; Brière J; Brice P
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2023-30. PubMed ID: 24965842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.
    Allen-Auerbach M; Quon A; Weber WA; Obrzut S; Crawford T; Silverman DH; Ratib O; Phelps ME; Czernin J
    Mol Imaging Biol; 2004; 6(6):411-6. PubMed ID: 15564152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma.
    Fujiwara H; Maeda Y; Nawa Y; Yamakura M; Ennishi D; Miyazaki Y; Shinagawa K; Hara M; Matsue K; Tanimoto M
    Eur J Haematol; 2011 Aug; 87(2):123-9. PubMed ID: 21557776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the (18)F-fluorodeoxyglucose-positron emission tomography era.
    Gonçalves Mde C; de Paula HM; Linardi Cda C; Cerci JJ; Aldred VL; Siqueira SA; Buccheri V; Zerbini MC
    Leuk Lymphoma; 2015; 56(10):2883-8. PubMed ID: 25697914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?
    Raanani P; Shasha Y; Perry C; Metser U; Naparstek E; Apter S; Nagler A; Polliack A; Ben-Bassat I; Even-Sapir E
    Ann Oncol; 2006 Jan; 17(1):117-22. PubMed ID: 16192294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT.
    Akkas BE; Vural GU
    Nucl Med Commun; 2013 Jan; 34(1):50-6. PubMed ID: 23111376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
    Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement.
    Abenavoli EM; Linguanti F; Anichini M; Miele V; Mungai F; Palazzo M; Nassi L; Puccini B; Romano I; Sordi B; Sciagrà R; Simontacchi G; Vannucchi AM; Berti V
    Hematol Oncol; 2024 Mar; 42(2):e3261. PubMed ID: 38454623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy.
    Luminari S; Cesaretti M; Tomasello C; Guida A; Bagni B; Merli F; Postiglione R; Mangone L; Versari A; Re F; De Lisi V; Ruffini L; Ferretti S; Cuneo A; Federico M
    Leuk Lymphoma; 2011 Sep; 52(9):1689-96. PubMed ID: 21663500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study.
    Picardi M; Soricelli A; Pane F; Zeppa P; Nicolai E; De Laurentiis M; Grimaldi F; Rotoli B
    Radiology; 2009 May; 251(2):574-82. PubMed ID: 19401581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
    Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
    Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Is ceCT necessary beyond FDG-PET/CT for primary staging in Hodgkin lymphoma?].
    Kajáry K; Molnár Z; Szakáll S; Molnár P; Lengyel Z
    Orv Hetil; 2014 Feb; 155(6):226-30. PubMed ID: 24486846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
    Carrillo-Cruz E; Marín-Oyaga VA; Solé Rodríguez M; Borrego-Dorado I; de la Cruz Vicente F; Quiroga Cantero E; Manzanares Pérez M; Capote FJ; Ramírez Sánchez MJ; Espigado Tocino I; Pérez-Vega H; Vázquez-Albertino R; Pérez-Simón JA
    Eur J Haematol; 2015 Jan; 94(1):23-30. PubMed ID: 24520874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.